Devyser Diagnostics AB publishes quarterly report for the period January to March 2023
“The first quarter of the year saw continued strong growth, record gross margin and the launching of our first IVDR-approved product. After the end of the quarter, we were also able to announce an exclusive collaboration and distribution agreement with US-based Thermo Fisher Scientific. The agreement gives patients quick access to our transplant products and strengthens our global presence.” Fredrik Alpsten, CEO, Devyser The quarter from January to March 2023 · Net sales amounted to SEK 39.5 million (30.4), corresponding to a 29.9% increase. Adjusted for exchange rate